Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition

Citi upgraded Blueprint Medicines (BPMC) to Neutral following Sanofi's (SNY) $9.5 billion acquisition announcement at $129 per share plus contingent value rights; the deal aims to bolster Sanofi's rare immunological disease portfolio. The acquisition, expected to close in Q3 2025, has prompted rating adjustments from multiple firms, including downgrades from Citizens JMP, TD Cowen and JP Morgan, while Citi set a price target of $129. Blueprint reported strong Q1 2025 revenues for Ayvakit, reaching nearly $150 million.

Analysis

Sanofi is acquiring Blueprint Medicines (BPMC) for $129 per share in cash plus up to $6 per share in contingent value rights (CVRs) for BLU-808, a deal valued at approximately $9.5 billion aimed at bolstering Sanofi's rare immunological disease franchise. BPMC's stock surged 34% in the past week to trade near its $128.15 52-week high and the offer price, reflecting the market's pricing of the deal; its market capitalization reached $8.25 billion. Analyst reactions have generally involved aligning price targets with the offer, with Citi upgrading BPMC to Neutral with a $129 price target, while other firms such as Citizens JMP, TD Cowen, and JPMorgan adjusted ratings to Hold or Market Perform due to the capped upside. Blueprint's fundamentals show strength, evidenced by 99% revenue growth over the last twelve months, a healthy current ratio of 2.8, and nearly $150 million in net revenues for Ayvakit in the first quarter of 2025. While pivotal data from Cogent’s SUMMIT trial in July for bezuclastinib could impact valuation perceptions of Blueprint’s systemic mastocytosis assets, Citi analysts do not foresee regulatory issues or competing bids hindering the transaction's expected close in Q3 2025.

Key Decisions for Investors

• Investors should recognize that with Blueprint Medicines' stock trading close to the $129 per share cash offer from Sanofi, further significant upside is largely limited to the potential realization of the contingent value rights for BLU-808, which could add up to $6 per share.
• Careful consideration should be given to the risk-reward profile of these CVRs, as their value is dependent on future development and regulatory milestones, and the acquisition's expected close in Q3 2025 ties up capital for an extended period.
• Monitoring the outcome of Cogent’s SUMMIT trial for bezuclastinib in July is prudent, as it may provide further insight into the underlying value of Blueprint's pipeline assets, even though the Sanofi transaction is anticipated to proceed without disruption.